.
CRSP financial statements
* Numbers in millions
Year |
2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|
Capitalization * |
217 | 1 670 | 1 546 | 2 851 | 10 928 | 4 051 |
EV * |
-98 | 1 431 | 1 090 | 1 916 | 9 821 | 9 821 |
Stock price $ |
17.74 | 41.7 | 32.24 | 52.42 | 165.7 | 61.42 |
Number of shares * |
12 | 40 | 48 | 54 | 66 | 66 |
EPS |
-1,89 | -1,71 | -3,44 | 1,23 | -5,29 | -5,29 |
Revenue * |
5 | 41 | 3 | 290 | 1 | 1 |
Net income * |
-23 | -68 | -165 | 67 | -349 | -349 |
Operating profit * |
-68 | -65 | -159 | 47 | -354 | -354 |
Total liabilities * |
112 | 84 | 97 | 127 | 164 | 164 |
Net debt * |
-316 | -240 | -457 | -891 | -1 107 | -1 107 |
Total assets * |
345 | 271 | 489 | 1 067 | 1 828 | 1 828 |
Equity * |
233 | 188 | 392 | 939 | 1 664 | 1 664 |
Cash and investments * |
316 | 240 | 457 | 944 | 1 690 | 1 690 |
Over the past 10 years, the maximum capitalization of CRISPR Therapeutics AG is 10 928, the minimum is 217. Maximum net income 67, Minimum net income -349. The maximum price of CRSP shares is 165.7, the minimum price is 17.74.
.
CRSP valuation
Year |
2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|
P/E |
-9,37 | -24,44 | -9,37 | 42,65 | -31,32 | -11,61 |
P/B |
0,93 | 8,89 | 3,94 | 3,04 | 6,57 | 2,43 |
P/S |
42,11 | 40,74 | 495,00 | 9,85 | 15 198,70 | 5 633,70 |
E/P |
-11% | -4% | -11% | 2% | -3% | -9% |
P/FCF |
-3,73 | -21,44 | -15,62 | 57,03 | -42,57 | -15,78 |
.
CRSP profitability
Year |
2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|
ROE |
-10% | -36% | -42% | 7% | -21% | |
ROA |
-7% | -25% | -34% | 6% | -19% | |
ROIC |
-21% | -25% | -34% | 5% | -20% |